Clinical syndromes and consequences of antiretroviral-related hepatotoxicity (Q37784777)

23 August 2017

title

Clinical syndromes and consequences of antiretroviral-related hepatotoxicity (English)

1 reference

23 August 2017

main subject

anti-retroviral agent

0 references

1 reference

Marina Núñez

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

full work available at URL

23 August 2017

https://aasldpubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.23716

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20812358

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.23716

5 July 2024

1 reference

https://api.crossref.org/works/10.1002/HEP.23716

https://onlinelibrary.wiley.com/doi/full/10.1002/hep.23716

5 July 2024

1 reference

https://api.crossref.org/works/10.1002/HEP.23716

5 July 2024

1 reference

23 August 2017

volume

52

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

1143-1155

1 reference

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Drug-induced liver injury associated with HIV medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Highly active antiretroviral therapy-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Diagnosis, management and prevention of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Outcome and prognostic markers in severe drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Current concepts of mechanisms in drug-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Regulatory mechanisms controlling gene expression mediated by the antioxidant response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Endoplasmic reticulum stress and liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Mechanisms of drug-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity of nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Drug-induced liver injury: mechanisms and test systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Jaundice and hepatocellular damage associated with nevirapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

DRESS syndrome associated with nevirapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Abacavir hypersensitivity reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Lactic acidosis in HIV infected patients: a systematic review of published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Direct analysis of mitochondrial toxicity of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Nodular regenerative hyperplasia of liver as a consequence of ART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Non-alcoholic fatty liver disease and the metabolic syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity due to mitochondrial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Etiopathogenesis of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatic steatosis in HIV–HCV coinfected patients: analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

HLA-Cw8 primarily associated with hypersensitivity to nevirapine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Advanced Liver Fibrosis in HIV/HCV-Coinfected Patients on Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Riboflavin to treat nucleoside analogue-induced lactic acidosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

Hepatic encephalopathy as an unusual late complication of transjugular intrahepatic portosystemic shunt insertion for non-cirrhotic portal hypertension caused by nodular regenerative hyperplasia in an HIV-positive patient on highly active antiretrov

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23716

7 January 2021

A near-fatal hypersensitivity reaction to abacavir: case report and literature review

https://api.crossref.org/works/10.1002/HEP.23716

62

1 reference

Liver toxicity warning for darunavir

5 July 2024

https://api.crossref.org/works/10.1002/HEP.23716

75

1 reference

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

5 July 2024

https://api.crossref.org/works/10.1002/HEP.23716

76

1 reference

Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs

5 July 2024

https://api.crossref.org/works/10.1002/HEP.23716

100

1 reference

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients

5 July 2024

https://api.crossref.org/works/10.1002/HEP.23716

113

1 reference

Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis

5 July 2024

https://api.crossref.org/works/10.1002/HEP.23716

136

1 reference

5 July 2024

Identifiers

DOI

10.1002/HEP.23716

1 reference

23 August 2017

1 reference